Adrienn N. Bourkas

Adrienn N. Bourkas

Auto-generated profile, based on publicly available information

Adrienn N. Bourkas

School of Medicine, Queen’s University, Kingston, ON, Canada

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2024 in Journal of Cutaneous Medicine and Surgery
Verified
Journal Article
Open access
RGRyan S. Q. Geng
Ryan S. Q. Geng
ABAdrienn N. Bourkas
Adrienn N. Bourkas
AMAsfandyar Mufti
Asfandyar Mufti
RSR. Gary Sibbald
R. Gary Sibbald
Rosacea is a chronic inflammatory condition of which there is no cure. The pathogenesis of rosacea is likely multifactorial, involving genetic and environmental contributions. Current understanding suggests that pro-inflammatory pathways involving cathelicidins and inflammasome complexes are central to rosacea pathogenesis. Common rosacea triggers modulate these pathways in a complex manner, which may contribute to the varying severity and clinical presentations of rosacea. Established and emerging rosacea treatments may owe their efficacy to their ability to target different players in these pro-inflammatory pathways. Improving our molecular understanding of rosacea will guide the development of new therapies and the use of combination therapies.

11 August 2023 in BMJ Open
Verified
Journal Article
Open access
PDF file
ABAdrienn N Bourkas
Adrienn N Bourkas
NBNatasha Barone
Natasha Barone
MBMatthew E C Bourkas
Matthew E C Bourkas
MMMatthew Mannarino
Matthew Mannarino
RFRobert D J Fraser
Robert D J Fraser
Jose Luis Ramirez-GarciaLunaJose Luis Ramirez-GarciaLuna
Jose Luis Ramirez-GarciaLuna
Objectives To compare teledermatology and face-to-face (F2F) agreement in primary diagnoses of dermatological conditions. Design Systematic review and meta-analysis Methods MEDLINE, Embase, Cochrane Library (Wiley), CINAHL and medRxiv were searched between January 2010 and May 2022. Observational studies and randomised clinical trials that reported percentage agreement or kappa concordance for primary diagnoses between teledermatology and F2F physicians were included. Titles, abstracts and full-text articles were screened in duplicate. From 7173 citations, 44 articles were included. A random-effects meta-analysis was conducted to estimate pooled estimates. Primary outcome measures were mean percentage and kappa concordance for assessing diagnostic matches between teledermatology and F2F physicians. Secondary outcome measures included the agreement between teledermatologists, F2F dermatologists, and teledermatology and histopathology results. Results 44 studies were extracted and reviewed. The pooled agreement rate was 68.9%, and kappa concordance was 0.67. When dermatologists conducted F2F and teledermatology consults, the overall diagnostic agreement was significantly higher at 71% compared with 44% for non-specialists. Kappa concordance was 0.69 for teledermatologist versus specialist and 0.52 for non-specialists. Higher diagnostic agreements were also noted with image acquisition training and digital photography. The agreement rate was 76.4% between teledermatologists, 82.4% between F2F physicians and 55.7% between teledermatology and histopathology. Conclusions and relevance Teledermatology can be an attractive option particularly in resource-poor settings. Future efforts should be placed on incorporating image acquisition training and access to high-quality imaging technologies. Trial registration number 10.17605/OSF.IO/FJDVG

28 November 2022 in Sage Open Medical Case Reports
Verified
Journal Article
Open access
ABAdrienn N Bourkas
Adrienn N Bourkas
CSCathryn Sibbald
Cathryn Sibbald
This case report describes the first successful treatment of alopecia areata and atopic dermatitis with the Janus kinase 1 inhibitor upadacitinib in a paediatric patient. After minimal response to topical corticosteroids and spironolactone, improvements in hair growth on the scalp and body were noted after only 6 weeks of upadacitinib treatment.

1 April 2023 in JCO Oncology Practice
Verified
Journal Article
Closed access
ABAdrienn N. Bourkas
Adrienn N. Bourkas
AMAlexandre Menard
Alexandre Menard
ETEmidio Tarulli
Emidio Tarulli
LJLeah Jodoin
Leah Jodoin
JBJames J. Biagi
James J. Biagi
PURPOSE: The Accelerated Diagnostic Assessment Program (ADAP) manages patients with imaging abnormalities, with or without concomitant symptoms, where cancer is suspected. The ADAP is offered to primary care practitioners and emergency departments with cases triaged by a medical oncologist. METHODS: We performed a retrospective patient chart review of electronic medical records from January 2019 until June 2021 to validate the program. We collected information on the referral pathways, patient demographics, wait-times, and diagnostic results. The control group consisted of outpatients who were referred for biopsy over a 1-year period outside the ADAP stream. Statistical analyses were performed using IBM SPSS software. RESULTS: Of the 97 patients included, 54% were female, with ages ranging from 18 to 96 years. Twenty-nine percent (n = 20) of the malignant cases were incidental findings. Most patients referred to the ADAP were diagnosed with a malignancy (71%; n = 69), comprising hematologic (45%; n = 31), GI (26%; n = 18), or other cancers (29%; n = 20). The ADAP had decreased wait-times from referral to biopsy collection (17.6 days ± 10.7 [standard deviation (SD)]; n = 43) when compared with the control group (41.2 days ± 40.0 [SD]; n = 67; P < .001). ADAP patients with malignancies saw a treating specialist 7.6 ± 7.6 days [SD] after their follow-up appointment at the ADAP. CONCLUSION: The ADAP accelerated time to biopsy in a statistically significant manner when compared with age-, referring physician–, and biopsy site–matched controls. It also outperformed national and provincial standards, suggesting that its model addresses a gap in care by providing an underserved population timely access to diagnosis and treatment.

19 January 2023 in Pediatric Dermatology
Verified
Journal Article
Closed access
ABAdrienn N. Bourkas
Adrienn N. Bourkas
EPElena Pope
Elena Pope
RMRoberto Mendoza‐Londono
Roberto Mendoza‐Londono
BKBinita M. Kamath
Binita M. Kamath
ILIrene Lara‐Corrales
Irene Lara‐Corrales

1 January 2023 in Sage Open Medical Case Reports
Verified
Journal Article
Open access
ABAdrienn N Bourkas
Adrienn N Bourkas
RGRyan Geng
Ryan Geng
MSMatthew Sibbald
Matthew Sibbald
RSR Gary Sibbald
R Gary Sibbald
An 18-year-old female with a history of atopic march, hyperhidrosis, and eosinophilic esophagitis was diagnosed with erythromelalgia and gastrointestinal dysautonomia secondary to presumed autoimmune small fiber neuropathy. The patient experienced significant clinical improvements after the initiation of intravenous immunoglobulin therapy, supporting an underlying autoimmune disorder.